{"data":{"id":"us-il/410-ilcs-416-25","jurisdiction":"us-il","citation":"410 ILCS 416/25","heading":"Reimbursement requirements; notice.","body":"(a) A reimbursement under the program at a trial site that conducts clinical trials must:\n(1) be reviewed and approved by the institutional review board associated with the clinical trial for which the reimbursement is provided; and\n(2) comply with applicable federal and State laws.\n(b) The independent third-party organization operating the program is not required to obtain approval from an institutional review board with respect to the financial eligibility of a subject who is medically eligible for a clinical trial.\n(c) The independent third-party organization operating the program shall provide written notice to a subject on:\n(1) the nature, availability, and scope of the ancillary financial support under the program; and\n(2) the program's general guidelines on financial eligibility.","path":["CHAPTER 410 PUBLIC HEALTH","Clinical Trial Participation Program Act."],"source_url":"https://www.ilga.gov/legislation/ILCS/details?ActID=4047\u0026ChapterID=35\u0026ChapAct=FullText\u0026Print=True","current_through":"at least Public Act 104-790","vintage":"","retrieved_at":"2026-09-15T04:46:35Z","sha256":"93a27282103837fbcf657337e978eb07cdcae00cfa604c23116c0c47d20b2a5f","source_id":"us-il","stale":false,"prev":"us-il/410-ilcs-416-20","next":"us-il/410-ilcs-416-30"},"notice":"GroundRules: Original legal text. Not legal advice."}